Nanologica is launching a subsidiary to conduct the clinical trial for NIC-001 in Australia.
In 2019, an expanded market analysis was conducted regarding Nanologica’s project in gastropares, NIC-001, after which the company chose to focus its upcoming market for the product to North America. In consultation with experts in the field, it was decided to place the clinical program in Australia, as this is considered favorable from a regulatory, quality and cost perspective, states the company.
A local subsidiary
In order to be able to carry out the study in Australia, a local subsidiary is started and work on incorporating the company has now begun.
The study aims to measure the amount of substance in the blood in Nanologica’s sublingual preparation compared to the oral formulation currently available in the market. The results of the study can be expected by the end of 2020.
Photo of Andreas Bhagwani: Nanologica
